US Bancorp’s NewAmsterdam Pharma NAMS Stock Holding History

US Bancorp’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247K	Buy	7,286 +1,812	+33%	+$59.7K	﹤0.01%	1992
2026 Q1	$175K	Buy	5,474 +2,055	+60%	+$66.9K	﹤0.01%	2088
2025 Q4	$120K	Buy	3,419 +3,284	+2,433%	+$120K	﹤0.01%	2271
2025 Q3	$3.84K	Sell	135 -137	-50%	-$3.28K	﹤0.01%	3606
2025 Q2	$4.93K	Sell	272 -369	-58%	-$6.73K	﹤0.01%	3640
2025 Q1	$13.1K	Sell	641 -2,163	-77%	-$48.1K	﹤0.01%	3348
2024 Q4	$72.1K	Sell	2,804 -11,619	-81%	-$247K	﹤0.01%	2554
2024 Q3	$239K	Buy	14,423 +27	+0.2%	+$467	﹤0.01%	1943
2024 Q2	$277K	Buy	14,396 +7,935	+123%	+$159K	﹤0.01%	1828
2024 Q1	$153K	Buy	+6,461	New	+$131K	﹤0.01%	2141

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

US Bancorp's NAMS Position: Q2 2026 in Review

US Bancorp increased its NewAmsterdam Pharma (NAMS) stake by 33% in Q2 2026, buying an estimated $59.7K and bringing the position to 7,286 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

US Bancorp first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $277K in Q2 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

US Bancorp held 7,286 shares of NewAmsterdam Pharma worth $247K as of Q2 2026.
US Bancorp bought 1,812 NewAmsterdam Pharma shares in Q2 2026, an estimated $59.7K.
NewAmsterdam Pharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1992 holding.
US Bancorp first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
US Bancorp's NewAmsterdam Pharma position peaked at $277K in Q2 2024.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.